Atomoxetine (Systemic): New Hope for ADHD |
Atomoxetine Capsules is a new class of drug, approved recently by the FDA of USA for management of Attention Deficit Hyperactivity Disorder (ADHD). Its dosage is strictly under the supervision of a competent medical authority trained in such disorders, and licensed to use drugs of this class.
Atomoxetine is a selective norepinephrine
reuptake inhibitor. It reduces ADHD symptoms by blocking or slowing reabsorption
of norepinephrine, a brain chemical considered important in regulating
attention, impulsivity, and activity levels. Atomoxetine is
not a controlled substance, and in an abuse-potential study in adults, Atomoxetine
was not associated with stimulant or euphoriant
properties.
Clinical trials lasting 9 weeks to 1 year, comparing Atomoxetine to placebo have shown statistically significant improvement in symptoms of ADHD. However, the safety and efficacy of Atomoxetine in pediatric patients younger than 6 years of age have not been established.
Adults: constipation, dry mouth, nausea, decreased appetite, dizziness, insomnia, decreased libido, ejaculatory problems, impotence, urinary hesitation and/or urinary retention and/or difficulty in micturition, and dysmenorrhea.
Atomoxetine is eliminated primarily by oxidative metabolism through the
cytochrome P450 2D6 (CYP2D6) enzymatic pathway and subsequent glucuronidation.
Atomoxetine has a half-life of 5 hours.
This is a prescription-only drug, and the subject of dosing is best left to the clinician in charge of treating your child. It has interaction with other drugs whose metabolic action modifies the rate of activity of the above mentioned metabolic pathways. The dosage basically is dependent on the weight of the patient and degree of individual response, starting with a low dose and building up.
Click here to go to top |